Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BUILD UC phase 2a trial of PF-06687234 added to infliximab in active ulcerative colitis not in remission
MOH_2018-10-15_002516Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing PF-06687234 + infliximab with Placebo + infliximab (2 arms). Primary endpoint: Not reported. Started Jun 2018; status: completed.
02
Drugs
f8il10
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2018-10-15_002516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-10-15_002516.